African Americans have a high risk for type 2 diabetes. Genetic traits, the prevalence of obesity, and insulin resistance all contribute to the risk of diabetes in the African American community. African Americans have a high rate of diabetic complications, because of poor glycaemic control and racial disparities in health care in the USA. African Americans with diabetes may have an atypical presentation that simulates type 1 diabetes, but then their subsequent clinical course is typical of type 2 diabetes. Culturally sensitive strategies, structured disease management protocols, and the assistance of nurses, diabetic educators, and other health care professionals are effective in improving the outcome of diabetes in the African American community.

The estimated prevalence of diabetes in the USA is nearly 16 million people. Ninety percent of all people with diabetes in the USA have type 2 diabetes, and that percentage is even higher for patients over the age of 45 years. African Americans constitute an ethnic population that has been characterised by the American Diabetes Association as having a high risk for diabetes. The prevalence of diagnosed diabetes is 1.6-fold higher in African Americans compared with white Americans. While the incidence of type 1 diabetes is fourfold higher in white Americans compared with African Americans, the prevalence of type 2 diabetes is 1.4-fold to 2.3-fold higher in African Americans. The increased prevalence of type 2 diabetes among African Americans extends to children, adolescents and even to US military personnel on active duty. In addition, African Americans bear a disproportionate burden of the morbidity and mortality associated with diabetes. Consequently, diabetic African Americans have a higher rate of retinopathy, microalbuminuria, end stage renal disease, lower extremity amputation, and mortality compared with white Americans.

**RISK FACTORS**

The reasons for these findings are multifaceted. The most popular hypotheses that have been proposed are specific genetic factors and environmental factors. One genetic theory is that the prevalence of G6PD deficiency in African Americans in combination with a Western diet is a risk factor for type 2 diabetes. A more widely held theory is the thrifty gene theory. This theory suggests that populations that were subject to repeated periods of famine derived a survival advantage from a “thrifty” gene; that is, a genetic predilection for efficient storage of fat. Such fat storage would sustain the person until food became available again. If such a population now resides in a land of plenty, for example, the West African diaspora to America, then the same genetic trait for efficient fat storage would lead to obesity and consequent insulin resistance. However, native Africans are a heterogeneous group, and African Americans, after centuries of genetic admixture, are even more heterogeneous. For these, and other reasons, the thrifty gene hypothesis has been disputed.

Obesity is associated with insulin resistance and type 2 diabetes. Obesity is more prevalent among African Americans than white Americans. This is especially true for women; it is estimated that diabetes can be attributed to abdominal obesity in 39.9% of African American women, compared with 24.0% of white American women. Nevertheless, the increased prevalence of diabetes in African Americans cannot be accounted for solely by differences in weight.

Physical inactivity is a risk factor for type 2 diabetes, and physical activity is clearly beneficial for type 2 diabetes. Physical activity is decreased in African American women and adolescent girls. This also contributes to their risk for diabetes. Insulin resistance is a precursor to glucose intolerance and overt diabetes. The issue of insulin resistance among African Americans is quite problematic. African American children, especially girls, have a higher rate of insulin resistance than white children. However, among adults, some investigators have found similar rates of insulin resistance between African Americans and white Americans with type 2 diabetes. Other investigators have found a dichotomous population of diabetic African Americans, with half their patients exhibiting insulin resistance and half exhibiting insulin sensitivity. When non-diabetic African American subjects are studied, increased insulin resistance has been found in African American men and women, even after adjusting for body weight and fat distribution, in some studies, but only in non-obese African American women, compared with non-obese white women, in another study. The variability of results in these studies may be attributable to different methods of assessing insulin resistance.

**Abbreviations:** SES, socioeconomic status; DCCT, diabetes control and complications trial; UKPDS, United Kingdom prospective diabetes study; DPP, diabetes prevention program; DKA, diabetic ketoacidosis; MODY, maturity onset diabetes of the young
MORBIDITY
While there are multiple reasons for the increased prevalence of diabetes among African Americans, a prominent reason for the increased rate of complications among African American diabetic patients is the lack of adequate control. The diabetes control and complications trial (DCCT) and the United Kingdom prospective diabetes study (UKPDS) have clearly shown, in type 1 and type 2 diabetes, respectively, that improved glycemic control is associated with a lower risk of microvascular complications. Although the number of African Americans in the DCCT and the number of African Caribbean in the UKPDS was less than 10% of each study population, it is reasonable to assume that the findings of these studies are equally applicable to ethnic minorities.

Adult diabetic patients in the USA, of all races, are generally poorly controlled. However, racial differences in glycemic control have been amply reported: African American diabetic patients are less well controlled than white diabetic patients. African American diabetic patients are less likely to have their treatment intensified to improve glycemic control. One possible explanation for this phenomenon is that African Americans, as a group, have a lower socioeconomic status (SES) than white Americans. Indian patients have less access to health care and often present with diseases that are already far advanced. However, even when adjusting for SES, access to health care and severity of disease, racial differences in glycemic control persist.

Another important factor in the increased morbidity in African Americans with diabetes is racial disparities in health care. The Institute of Medicine (IOM) published an extensive report on the topic of disparities in health care in the USA. The IOM found that all racial and ethnic minorities in the USA receive a lower quality of health care, regardless of SES, insurance coverage, age, or comorbid conditions. In a study of Medicare beneficiaries, African American diabetic patients were less likely to have glycosylated haemoglobin measurements, lipid testing, or ophthalmological visits than white diabetic patients. All the subjects in this study were age 65 years or older and were enrolled in Medicare, a US government funded health insurance that is widely accepted by physicians in the USA. Thus, SES, age, and access to health care were not responsible for the discrepancy in quality of care. Similarly, a study of US military veterans with diabetes found a discrepancy in care. All the subjects received their primary care within the Veterans Affairs health care system; therefore, SES and access to care were not factors. Nevertheless, African American diabetic veterans were more likely to undergo a lower extremity amputation than white diabetic veterans. African American diabetic veterans are also more likely to have diabetic nephropathy and end stage renal disease than white diabetic veterans, after adjustment for age, sex, and economic status. A discussion of the myriad and complex causes and manifestations of racial and ethnic inequalities in the USA is beyond the scope of this review.

TREATMENT
The cornerstone of management of type 2 diabetes is lifestyle changes—that is, diet and exercise. Pharmacological intervention is always in addition to, not in place of lifestyle changes. The diabetes prevention program (DPP) showed that intensive lifestyle intervention is more effective than metformin in preventing the progression from impaired glucose tolerance to overt diabetes. The DPP was a prevention trial, rather than a therapeutic trial for patients already diagnosed with diabetes. Nevertheless, the DPP has the value of having been designed to intentionally recruit half of its participants from racial or ethnic minority groups.

Twenty per cent of the 3200 participants were African Americans. In a subgroup analysis of the DPP, there was no significant difference in treatment effects based on sex, race, or ethnic group. Studies of African Americans with type 2 diabetes have shown that improved levels of physical activities, effective medical nutrition treatment, and consequent improved glycemic control can be achieved with culturally appropriate strategies.

When lifestyle changes are insufficient for adequate glycemic control, pharmacological intervention is necessary. Discussing “evidence based” pharmacological recommendations for African American diabetic patients is a challenge because of the paucity of randomised controlled studies that specifically investigate African Americans. For example, despite the fact that biological responses to pharmaceuticals vary among different ethnic and racial groups, scarce data are available on the pharmacokinetics of oral antidiabetic drugs among African Americans. There are 10 oral antidiabetic drugs listed in the Physicians’ Desk Reference (PDR): the sulfonylureas—glyburide (glibenclamide), glipizide, and glimepiride; the biguanide—metformin; the thiazolidinediones—pioglitazone and rosiglitazone; the meglitinides—repaglinide and nateglinide; and the α-glucosidase inhibitors—acarbose and miglitol. The product information in the PDR for eight of the 10 agents has no information on the effects of race upon the pharmacokinetics of the drug. The product information for six of 10 agents has no information on the effects of race upon drug efficacy. Four agents have product information stating that the efficacy of the drug is unaffected by race. African Americans constitute from 9.3% to 21.5% of the patient population in the studies cited in these agents’ product information.

There are several excellent, recently published reviews of the pharmacological treatment of type 2 diabetes. These reviews detail the dose range, mode of action, adverse effects, and recommended use for the available pharmacological agents. The different classes of oral antidiabetic drugs have equivalent clinical efficacy, and most agents will lower HbA1C levels by 1%–2%. Combination treatment is synergistic and more effective than monotherapy. The underlying rationale for the selection of specific oral agents is the known pathophysiology of type 2 diabetes. The initial defect in type 2 diabetes is insulin resistance, but it is followed by a progressive decline in β cell function. The insulin resistance is manifest by accelerated hepatic glucose production and decreased muscle uptake of glucose. Impaired β function is manifested by impaired insulin secretion, failure to respond to oral agents, and ultimately a need for insulin treatment.

Metformin is recommended as initial treatment for most type 2 diabetic patients, especially overweight patients. The fear of lactic acidosis with metformin treatment is no longer warranted. Sulfonylureas are often preferred for lean type 2 diabetic patients who seem to be more insulin deficient than insulin resistant. Thiazolidinediones have been used successfully as monotherapy for the insulin resistant patient or in combination therapy with sulfonylureas, metformin, and insulin. The α-glucosidase inhibitors have prominent gastrointestinal side effects that limit their tolerance by patients. The α-glucosidase inhibitors and the meglitinides are used primarily to dampen postprandial glycaemic excursions.

An evolving concept is the use of combination therapy earlier in the management of type 2 diabetes. The array of available oral agents with different mechanisms of action results in several synergistic combinations, and combination...
therapy may permit lower doses of each individual agent and hence fewer side effects.60

Of course, all of the above is predicated upon studies that primarily enrolled white subjects. A Medline search for randomised controlled trials of African American diabetic patients resulted in only four citations.61–64 Three of the four studies involved African Americans who did not have diabetes, but were at increased risk for diabetes by dent of glucose intolerance, a family history of diabetes, or a history of gestational diabetes.62 64 65 Two of these three papers studied glipizide, and the third studied troglitazone, which is no longer available. The fourth paper involved insulin treated African Americans with type 2 diabetes, and studied the effects of pramlintide.66 Pramlintide is an amylin analogue that suppresses glucagon secretion, but it is not commercially available. In the absence of specific evidence, the recommendations for the use of oral antidiabetic drugs in African Americans with type 2 diabetes are, by default, the same as the recommendations for the general population.59 60–62

Insulin therapy, either alone or in combination with oral agents, improves glycaemic control in type 2 diabetes.61–64 This may be particularly true for African Americans with type 2 diabetes.65 Certainly, patients who fail to respond to oral agents will need insulin therapy, and lean patients with type 2 diabetes are more likely to require insulin therapy early in the course of their disease.66 When NPH insulin is prescribed as a night time dose, it is best taken at bedtime rather than dinner time.67 Combinations of insulin with oral agents often permit lower doses of insulin,68 but such combinations are not always more effective than insulin alone.69 The major side effects of insulin therapy are weight gain and hypoglycaemia. These side effects are also the major barriers to the start of insulin therapy by physicians and important barriers to the acceptance of insulin therapy by patients. Insulin glargine, the once daily “basal” insulin, has been compared with NPH insulin and found to effect improved glycaemic control with a significantly lower incidence of weight gain and hypoglycaemia, especially nocturnal hypoglycaemia.69 Insulin glargine has been successfully used in combination with oral agents in type 2 diabetes. It has also been efficacious in combination with pre-meal rapid acting insulins in both type 1 and type 2 diabetes.

Continuous subcutaneous insulin infusion (CSII) via insulin pumps has been, in the author’s experience, equally effective in African American and white type 1 diabetic patients. Brittle diabetic patients (characterised by erratic swings in glucose levels) can benefit from a more narrow range of glycaemic excursions consequent to CSII. CSII is particularly useful for patients whose lifestyles preclude regimented schedules, such as shift workers. Although CSII is primarily used in type 1 diabetic patients, it is also effective in type 2 diabetic patients who require insulin therapy. CSII should be started and managed by endocrinologists who have experience with insulin pump therapy. However, primary care physicians should keep in mind the usual indications for considering CSII: brittle diabetes, pronounced Dawn phenomenon, pregnancy or pre-conception planning, shift work, and erratic lifestyle.

A critical issue in the management of African American diabetic patients is the lack of appropriate intensification of treatment, both lifestyle changes and pharmacological therapy, to achieve adequate glycaemic control. Multiple reasons have been cited for this persistent problem. Patient related factors include poor compliance with self monitoring, poor adherence to treatment, economic factors such as costs of test strips and drugs, literacy rate, lack of diabetes education, and sociocultural factors. Physician related factors include physicians’ perceptions and/or bias in treating African American patients, communication barriers, as well as time constraints in a busy clinical practice. These factors are often interconnected, particularly when there is non-concordance of physician-patient ethnicity. For example, if a physician has a judgmental attitude toward an African American patient and a preconceived notion that the patient cannot or will not comply with a regimen, and consequently gives only perfunctory attention to that patient, such an attitude will be evident to the patient and fuel any distrust the patient may already have for the medical profession in general and for a physician of a different ethnicity in particular. In this circumstance, non-compliance with treatment becomes a self fulfilling prophecy. In addition, although studies have shown that African American diabetic patients are less compliant with pharmacological treatment than white diabetic patients, medication compliance in itself may simply be a surrogate for better or more intensive diabetes education for a given patient. Also, while studies have correlated non-compliance with poor glycaemic control, non-compliance alone does not account for the full extent of racial differences in glycaemic control.66

Fortunately, strategies have been developed to overcome some of the barriers that prevent adequate management of diabetes in African Americans.66 67–71 Such strategies have been proved effective in various venues, including a large prepaid health plan with enrollees who are employed,67 community clinics for indigent patients,68 hospital based diabetes clinics,69 70 71 and a university based primary care clinic.68 One interesting strategy is the use of commercially available rapid HbA1c assays. Physicians who have access to current HbA1c data at the time that a patient is seen are more likely to appropriately intensify treatment than physicians who do not have contemporaneous access to HbA1c data.74 Most successful strategies have a prominent common theme: the utility of nurses, pharmacists, dietitians, and diabetes educators working with protocols and treatment algorithms, under the supervision of endocrinologists.69–73 Nurses and other allied health care professionals are often able to spend more time with patients, often have better communication skills, and may even be more compassionate than physicians.72 They are also more likely to adhere to treatment algorithms and to intensive therapy appropriately. Studies have shown the benefits of time and effort spent on telephoning patients between visits, re-scheduling missed appointments, facilitating transportation to clinics, communicating with referring physicians, and facilitating appointments with ancillary services (for example, podiatry, ophthalmology).71–73 This is, of course, time consuming and labour intensive. However, the long term gain, in terms of improved glycaemic control and reduced morbidity and mortality, is well worth the short term expense.

CHILDREN

African American children and adolescents with diabetes can present special challenges. The clinician should recognise that not all diabetes presenting in childhood or adolescence is type 1 diabetes. There is a rising incidence of type 2 diabetes in this age group, because of a rising incidence of obesity.75 The differential diagnosis of childhood or adolescent diabetes includes classic type 1 diabetes, maturity onset diabetes of the young (MODY), typical type 2 diabetes, and the atypical diabetes seen in African Americans.75–77

Typical type 1 diabetes is associated with islet cell autoantibodies and often presents with diabetic ketoacidosis (DKA). Classic MODY occurs predominantly in white youth, under the age of 25 years. However, less than 5% of childhood diabetes among white diabetic children is attributable to MODY. MODY is inherited as an autosomal dominant trait. At least eight different genetic mutations have been described.79 MODY is considered a form of type 2 diabetes.
in that it is non-ketotic and generally non-insulin requiring. Typical type 2 diabetes in children and teenagers of all races is associated with abdominal obesity, decreased physical activity, and insulin resistance. Atypical diabetes may constitute 10% of African American diabetic youth and is quite similar to the atypical diabetes in African American adults (vida infra). Unlike classic type 1 diabetes or MODY, 50% of African American youth with atypical diabetes are obese. Also unlike type 1 diabetes, these patients lack islet cell autoantibodies and have a subsequent clinical course that is similar to type 2 diabetes. However, unlike typical type 2 diabetes, atypical diabetes generally presents acutely, often with weight loss and ketosis.

The management of children and teenagers with diabetes can be difficult. Nevertheless, tight control is warranted to prevent microvascular, and possibly macrovascular complications. As for adult diabetic patients, lifestyle changes and pharmacological therapy is required for type 2 diabetes in the young. Insulin therapy has been widely used for type 2 diabetic youth. Insulin therapy is particularly useful when it is still unclear whether a patient has type 1 or type 2 (especially atypical) diabetes. Metformin therapy has been increasingly used to treat type 2 diabetes in teenagers. Unfortunately, African American youth with either type 1 or type 2 diabetes are less well controlled than white diabetic youth. Standard hospital based or subspecialty clinic based protocols have had disappointing results in managing young African American diabetic patients. However, the importance and efficacy of family support in improving diabetic control among African American youth has been shown. When a family member or caregiver is consistently involved in the management of the child’s diabetes and actively supervises the child’s care, HbA1c levels are significantly improved, compared with children whose caregivers only sporadically participate in their diabetes management.

**ATYPICAL DIABETES**

A review of diabetes in the African American community would not be complete without a discussion of the “atypical” diabetes that has been described in this population. African Americans with type 2 diabetes have been found to have two distinctive atypical features. The first is that adult African American diabetics may present with classic signs and symptoms of DKA and thus look like type 1 diabetic patients. However, unlike type 1 diabetic patients: (1) these patients have no autoimmune markers of type 1 diabetes; (2) they are often obese; (3) there is evidence of insulin resistance; and (4) most importantly, after intensive therapy, spontaneous remission is the rule, with restoration of β cell function within months and maintenance of normoglycemia with oral agents or only dietary treatment. These patients have impaired insulin secretion when admitted with DKA, but their subsequent clinical course is typical of type 2 diabetes. Recurrence of DKA is infrequent. Among those patients who remain insulin-requiring, recurrence of DKA is most often caused by non-compliance with insulin therapy.

The other unique feature of diabetes in African Americans is that spontaneous remission is also seen among patients who are not ketogenic. When adult African Americans with newly diagnosed type 2 diabetes receive an average of three months of intensive, multidisciplinary therapy, 30%–40% of these patients will go into remission—that is, they will achieve normoglycemia without pharmacological therapy. Those who remit have a significantly greater return of β cell function. However, there are no clinical characteristics that can differentiate those who will remit from those who will not. There is evidence that these atypical features are also present in African American children and adolescents with type 2 diabetes.

It bears remembering that the African American diabetic patient who is initially controlled with insulin need not necessarily remain insulin therapy, and the African American diabetic patient who is initially controlled with oral agents need not necessarily remain on pharmacological therapy.

**METABOLIC SYNDROME**

Syndrome X was promulgated by Reaven in an address to the American Diabetes Association. Reaven recognised the association of insulin resistance and hyperinsulinaemia with heart disease. He postulated a causal relation between hyperinsulinaemia and hypertension, dyslipidaemia, and coronary artery disease. This syndrome has been called by many names: syndrome X, metabolic syndrome X, insulin resistance syndrome, dysmetabolic syndrome, multiple metabolic syndrome, and deadly quartet. Currently, this clustering

---

**Key points**

- The prevalence of type 2 diabetes is higher in African Americans compared with white people, and African Americans bear a disproportionate burden of the morbidity and mortality associated with diabetes.
- Racial differences in glycaemic control have been reported. Racial and ethnic minorities in the USA receive lower quality health care.
- There is a paucity of randomised controlled studies that specifically investigate pharmacological treatment of African American diabetic patients.
- African Americans with atypical diabetes can present with diabetic ketoacidosis, but have a subsequent clinical course typical of type 2 diabetes.
- Intensive treatment of African Americans with newly diagnosed diabetes can lead to remission of diabetes in 30%–40% of patients.
- The use of case management nurses and structured disease management protocols can significantly improve glycaemic control and diabetes outcomes among African American diabetic patients.

**Key references**

of risk factors is now defined as the metabolic syndrome. The criterion proposed for the diagnosis of the metabolic syndrome is the presence of three or more of the following abnormalities: (1) abdominal obesity: waist circumference >102 cm in men and >88 cm in women; (2) hypertriglyceridaemia: ≥ 1.69 mmol/l; (3) low levels of high density lipoprotein (HDL) cholesterol: <1.04 mmol/l in men and <1.29 mmol/l in women; (4) hypertension: blood pressure ≥130/85 mm Hg; and (5) high fasting glucose: ≥6.1 mmol/l.

While some investigators have questioned a specific insulin resistance syndrome among African Americans, others have found ample support for the existence of the metabolic syndrome in the African American community. The importance of the metabolic syndrome is that this particular clustering of specific abnormalities is especially predictive of both overt diabetes and accelerated cardiovascular risk, and cardiovascular disease is the leading cause of death in diabetic patients. This is particularly relevant to African Americans who have the highest mortality rate from coronary artery disease of any ethnic group in the USA. The age adjusted prevalence of the metabolic syndrome among US adults is 24%. African American men have a lower prevalence compared with white men (16% vs 25%), but African American women have a higher prevalence compared with white women (26% vs 23%).

The metabolic syndrome can be effectively treated by lifestyle changes—that is, weight reduction and increased physical activity—which are capable of improving all of the components of the syndrome. Although, lifestyle changes constitute the first line of treatment, they are often insufficient to fully reverse all the abnormalities of the metabolic syndrome. Pharmacological treatment may be necessary to achieve the desired goals of lipid levels, blood pressure, and glucose levels. Multiple drug therapy directed at these individual components is recommended. Preliminary studies have found thiazolidinediones, metformin, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers to be effective, to varying degrees, in improving insulin sensitivity, reducing cardiovascular risk, and inhibiting the progression to overt diabetes. However, there are no evidence base data to support the use of any single agent to treat the metabolic syndrome.

CONCLUSION
African American adults, adolescents, and children have a high risk for, and a high prevalence of insulin resistance and overt type 2 diabetes mellitus. African American diabetic patients receive lower quality health care, are less well controlled, and consequently have a higher rate of complications than white diabetic patients. Some African American diabetic patients have an atypical presentation that simulates type 1 diabetes, but their subsequent clinical course is typical of type 2 diabetes. There is a paucity of evidence based data on pharmacological treatment for African American diabetic patients. However, primary care of the African American diabetic patient can be greatly assisted by structured disease management protocols. The use of case management nurses, diabetes educators, and other health care professionals is particularly effective in improving glycaemic control in the African American diabetic community.

QUESTIONS (ANSWERS AT END OF REFERENCES)
1. An African American patient who presents with diabetic ketoacidosis will require lifelong insulin treatment.
2. The possible reasons for the prevalence of poor glycaemic control among African American diabetic patients include the following, except:
   - Racial disparities in health care result in lower quality care for African Americans.
   - A low socioeconomic status for most African Americans hinders access to health care.
   - African American diabetic patients receive less intensive pharmacological treatment than white diabetic patients.
   - A reduced efficacy of oral antidiabetic drugs has been reported in African American subjects.
   - Insulin is less likely to be effective in African American diabetic patients than white diabetic patients.
3. The metabolic syndrome is particularly important in the African American community because:
   - It is associated with an accelerated cardiovascular risk.
   - It is associated with a high rate of lower extremity amputation.
   - It can be effectively treated by single drug therapy.
   - There is no association with abdominal obesity.
4. All of the following statements are true, except:
   - Metformin is generally recommended as initial pharmacological treatment for obese diabetic patients.
   - There are scarce evidence based data on specific pharmacological treatment for African American diabetic patients.
   - Lifestyle changes (diet and exercise) will not improve glycaemic control in African American diabetic patients.
   - Intensive treatment of a newly diagnosed African American diabetic patient may lead to remission of the diabetes.
5. Which of the following statements is true:
   - The thrifty gene theory refers to increased expenditure of calories in the face of increased calorific consumption.
   - There is a higher prevalence of autoimmune markers in African American diabetic patients than white diabetic patients.
   - African American children have a lower prevalence of diabetes resistance than white children.
   - African American women have a higher prevalence of the metabolic syndrome than white women.
Funding: none.
Conflicts of interest: none declared.

REFERENCES


ANSWERS
1. False; 2. (C); 3. false; 4. (A); 5. (C); 6. (D).